243 related articles for article (PubMed ID: 35436444)
1. SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.
Richardson SI; Madzorera VS; Spencer H; Manamela NP; van der Mescht MA; Lambson BE; Oosthuysen B; Ayres F; Makhado Z; Moyo-Gwete T; Mzindle N; Motlou T; Strydom A; Mendes A; Tegally H; de Beer Z; Roma de Villiers T; Bodenstein A; van den Berg G; Venter M; de Oliviera T; Ueckermann V; Rossouw TM; Boswell MT; Moore PL
Cell Host Microbe; 2022 Jun; 30(6):880-886.e4. PubMed ID: 35436444
[TBL] [Abstract][Full Text] [Related]
2. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
[TBL] [Abstract][Full Text] [Related]
3. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
[TBL] [Abstract][Full Text] [Related]
4. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
[TBL] [Abstract][Full Text] [Related]
6. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
Front Immunol; 2022; 13():946318. PubMed ID: 35928813
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
[TBL] [Abstract][Full Text] [Related]
8. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
9. Diminished Neutralization Capacity of SARS-CoV-2 Omicron BA.1 in Donor Plasma Collected from January to March 2021.
Lin YJ; Evans DH; Robbins NF; Orjuela G; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
Microbiol Spectr; 2023 Aug; 11(4):e0525622. PubMed ID: 37289096
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent NK-cell and neutralizing antibody responses against the Spike protein of Wuhan-Hu-1 and Omicron BA.1 SARS-CoV-2 variants in vaccinated experienced and vaccinated naïve individuals.
Albert E; Fernández-Soto D; Giménez E; Casanovas JM; Zulaica J; Álvarez-Rodríguez B; Rusu L; Geller R; Reyburn HT; Navarro D
J Med Virol; 2023 Jul; 95(7):e28900. PubMed ID: 37403730
[TBL] [Abstract][Full Text] [Related]
11. Omicron infection enhances Delta antibody immunity in vaccinated persons.
Khan K; Karim F; Cele S; Reedoy K; San JE; Lustig G; Tegally H; Rosenberg Y; Bernstein M; Jule Z; Ganga Y; Ngcobo N; Mazibuko M; Mthabela N; Mhlane Z; Mbatha N; Miya Y; Giandhari J; Ramphal Y; Naidoo T; Sivro A; Samsunder N; Kharsany ABM; Amoako D; Bhiman JN; Manickchund N; Abdool Karim Q; Magula N; Abdool Karim SS; Gray G; Hanekom W; von Gottberg A; ; Milo R; Gosnell BI; Lessells RJ; Moore PL; de Oliveira T; Moosa MS; Sigal A
Nature; 2022 Jul; 607(7918):356-359. PubMed ID: 35523247
[TBL] [Abstract][Full Text] [Related]
12. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources.
Sullivan DJ; Franchini M; Joyner MJ; Casadevall A; Focosi D
Nat Commun; 2022 Oct; 13(1):6478. PubMed ID: 36309490
[TBL] [Abstract][Full Text] [Related]
13. Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.
Lechmere T; Snell LB; Graham C; Seow J; Shalim ZA; Charalampous T; Alcolea-Medina A; Batra R; Nebbia G; Edgeworth JD; Malim MH; Doores KJ
mBio; 2022 Apr; 13(2):e0379821. PubMed ID: 35297676
[TBL] [Abstract][Full Text] [Related]
14. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
[TBL] [Abstract][Full Text] [Related]
15. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
[TBL] [Abstract][Full Text] [Related]
16. Reduced neutralization and Fc effector function to Omicron subvariants in sera from SARS-CoV-1 survivors after two doses of CoronaVac plus one dose subunit vaccine.
Chen D; Li X; Hao X; Qiu Y; Song Y; Sun H; Liu Y; Du J; Zhang Y; Xiao F; Song C; Yan Y; Song R; Wang X; Zhao X; Jin R
J Med Virol; 2023 Oct; 95(10):e29136. PubMed ID: 37804496
[TBL] [Abstract][Full Text] [Related]
17. Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs.
Bekliz M; Adea K; Vetter P; Eberhardt CS; Hosszu-Fellous K; Vu DL; Puhach O; Essaidi-Laziosi M; Waldvogel-Abramowski S; Stephan C; L'Huillier AG; Siegrist CA; Didierlaurent AM; Kaiser L; Meyer B; Eckerle I
Nat Commun; 2022 Jul; 13(1):3840. PubMed ID: 35787633
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
19. Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
Lavezzo E; Pacenti M; Manuto L; Boldrin C; Cattai M; Grazioli M; Bianca F; Sartori M; Caldart F; Castelli G; Nicoletti M; Nieddu E; Salvadoretti E; Labella B; Fava L; Vanuzzo MC; Lisi V; Antonello M; Grimaldi CI; Zulian C; Del Vecchio C; Plebani M; Padoan A; Cirillo DM; Brazzale AR; Tonon G; Toppo S; Dorigatti I; Crisanti A
Genome Med; 2022 Jun; 14(1):61. PubMed ID: 35689243
[TBL] [Abstract][Full Text] [Related]
20. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
